Cupid invests in GII Healthcare Investment
GII is a leading investment firm with assets under management exceeding US$ 3.5 billion with presence across Saudi Arabia, UAE, Europe, USA and India
GII is a leading investment firm with assets under management exceeding US$ 3.5 billion with presence across Saudi Arabia, UAE, Europe, USA and India
The company’s largest center for medical device applications, serving the entire Asian market
Azelis will strengthen its presence in the domestic market by leveraging portfolio synergies, actively consolidating the business, and creating value for all stakeholders
The UK authorization is based on positive results from the Phase III OASIS-1, -2, and -3 trials
Takara Bio Europe will distribute MN’s Bioanalysis portfolio in Austria, Belgium, Denmark, France, Germany, Ireland, Luxembourg, Sweden, Switzerland, and the United Kingdom
He has held senior leadership positions at Syngene International, Fujifilm Diosynth Biotechnologies, Thermo Fisher Scientific, Sartorius Stedim Biotech, and other leading organizations
These medicines are essential in preventing RhD immunisation during pregnancy
Commercial production is expected to begin soon
Vevzuo is authorized for the prevention of skeletal related events in adults with advanced malignancies involving bone
Subscribe To Our Newsletter & Stay Updated